AP NEWS

Akebia Therapeutics to Participate in Upcoming Investor Conferences

November 20, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2018--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in the following investor conferences:

The 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 12:30 p.m. Eastern Time at the Lotte New York Palace Hotel. Akebia will participate in a fireside chat discussion; and The Global Mizuho Investor Conference on Monday, December 3, 2018, at the Lotte New York Palace Hotel.

A replay of the webcast from the Piper Jaffray Healthcare Conference will be available on the company’s website at www.akebia.com the day following the conference. To access, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at  www.akebia.com, which does not form a part of this release.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005661/en/

CONTACT: John Garabo

Director, Corporate Communications

617-844-6130

jgarabo@akebia.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Akebia Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 11/20/2018 04:05 PM/DISC: 11/20/2018 04:05 PM

http://www.businesswire.com/news/home/20181120005661/en

AP RADIO
Update hourly